Suneetha Gottumukkala
Overview
Explore the profile of Suneetha Gottumukkala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benlarbi M, Richard J, Clemente T, Bourassa C, Tolbert W, Gottumukkala S, et al.
medRxiv
. 2025 Mar;
PMID: 40061344
While antiretroviral therapy efficiently suppresses viral replication, inflammation and immune dysfunction persist in some people living with HIV-1 (PLWH). Soluble gp120 (sgp120) has been detected in PLWH plasma and its...
2.
Richard J, Grunst M, Niu L, Diaz-Salinas M, Tolbert W, Marchitto L, et al.
bioRxiv
. 2024 Sep;
PMID: 39253431
HIV-1 envelope glycoproteins (Env) from primary HIV-1 isolates typically adopt a pretriggered "closed" conformation that resists to CD4-induced (CD4i) non-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC). CD4-mimetic compounds (CD4mcs)...
3.
Tauzin A, Marchitto L, Belanger E, Benlarbi M, Beaudoin-Bussieres G, Prevost J, et al.
J Virol
. 2024 Sep;
98(10):e0096024.
PMID: 39230306
Importance: There are several reasons that make it difficult to target the HIV reservoir. One of them is the capacity of infected cells to prevent the recognition of HIV-1 envelope...
4.
Tauzin A, Marchitto L, Belanger E, Benlarbi M, Beaudoin-Bussieres G, Prevost J, et al.
medRxiv
. 2024 Jun;
PMID: 38883797
CD4-mimetics (CD4mcs) are small molecule compounds that mimic the interaction of the CD4 receptor with HIV-1 envelope glycoproteins (Env). Env from primary viruses normally samples a "closed" conformation which occludes...
5.
Prevost J, Chen Y, Zhou F, Tolbert W, Gasser R, Medjahed H, et al.
Nat Commun
. 2023 Oct;
14(1):6710.
PMID: 37872202
The HIV-1 entry inhibitor temsavir prevents the viral receptor CD4 (cluster of differentiation 4) from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this, temsavir...
6.
Tolbert W, Chen Y, Sun L, Benlarbi M, Ding S, Manickam R, et al.
Front Immunol
. 2023 Jun;
14:1178355.
PMID: 37334379
SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019-2020....
7.
Prevost J, Chen Y, Zhou F, Tolbert W, Gasser R, Medjahed H, et al.
bioRxiv
. 2023 May;
PMID: 37131729
The HIV-1 entry inhibitor temsavir prevents CD4 from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this temsavir relies on the presence of a residue...
8.
Chen Y, Sun L, Ullah I, Beaudoin-Bussieres G, Anand S, Hederman A, et al.
Sci Adv
. 2022 Jul;
8(28):eabn4188.
PMID: 35857504
Soluble angiotensin-converting enzyme 2 (ACE2) constitutes an attractive antiviral capable of targeting a wide range of coronaviruses using ACE2 as their receptor. Using structure-guided approaches, we developed a series of...
9.
Chen Y, Sun L, Ullah I, Beaudoin-Bussieres G, Anand S, Hederman A, et al.
bioRxiv
. 2021 Nov;
PMID: 34845451
Soluble Angiotensin-Converting Enzyme 2 (ACE2) constitutes an attractive antiviral capable of targeting a wide range of coronaviruses utilizing ACE2 as their receptor. Here, using structure-guided approaches, we developed divalent ACE2...
10.
Richard J, Nguyen D, Tolbert W, Gasser R, Ding S, Vezina D, et al.
mBio
. 2021 Sep;
12(5):e0140521.
PMID: 34579568
In HIV-1 infection, many antibodies (Abs) are elicited to Envelope (Env) epitopes that are conformationally masked in the native trimer and are only available for antibody recognition after the trimer...